Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Biotheus Acquires Rights to TILT Bio's Chimeric Adenovirus

publication date: Jan 27, 2020

Biotheus, a Guangdong biotech, in-licensed greater China rights to an oncolytic virus from Finland's TILT Biotherapeutics. TILT's proprietary technology codes novel oncolytic viruses for cytokines. The candidate, TILT-123, is a human 5/3 chimeric adenovirus capable of replicating only in cells defective in retinoblastoma/p16 pathway, which are found in most human tumors. Biotheus is developing a broad portfolio of me-better/novel drugs focused on immuno-oncology and metabolic diseases. The company plans to out-license late-stage clinical and commercialization activities to global partners. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here